Hans-Michael Wolff

Title: Hans-Michael Wolff: Innovative Contributions to Transdermal Drug Delivery

Introduction:

Hans-Michael Wolff, a prolific inventor based in Monheim, DE, has made significant contributions to the field of transdermal drug delivery systems. With over 27 patents to his name, Wolff has revolutionized the way therapeutic substances are administered to patients. This article explores his latest patents, career highlights, and notable collaborations within the industry.

Latest Patents:

Among Wolff's recent patents, two remarkable inventions stand out. The first patent involves a method for adjusting the release of active agents in a transdermal delivery system. This innovation utilizes an additive in a biphasic layer to control the permeation rate of the active agent independently of its concentration. This advancement allows for precise control over the therapeutic effect.

Another prominent patent relates to a multi-day patch designed specifically for the transdermal administration of rotigotine, a medication used to treat Parkinson's disease, depression, fibromyalgia, and other conditions associated with dopaminergic neuron loss. This invention utilizes a solvent-based self-adhesive matrix layer with a specific coating weight and reservoir layer composition, ensuring the release of therapeutically effective amounts of rotigotine for at least three consecutive days.

Career Highlights:

Hans-Michael Wolff has enjoyed a successful career with notable contributions to the pharmaceutical industry. He has worked at various reputable companies, including UCB Pharma GmbH and Schwarz Pharma AG, where he had the opportunity to apply his expertise in the development and improvement of drug delivery systems. Wolff's dedication to enhancing transdermal therapies has brought him recognition and acclaim within the industry.

Collaborations:

Throughout his career, Wolff has had the opportunity to collaborate with esteemed colleagues, some of whom include Christoph Arth and Dietrich Wilhelm Schacht. These collaborations have fostered a rich environment of knowledge exchange and innovation within the field of transdermal drug delivery. The combined expertise of these individuals has undoubtedly contributed to the success of their projects, further solidifying Wolff's standing as an influential inventor.

Conclusion:

Hans-Michael Wolff's passion for innovation and commitment to advancing transdermal drug delivery systems have propelled him to the forefront of his field. With 27 patents to his name, including recent groundbreaking inventions in adjusting active agent release and multi-day patch technology, Wolff continues to reshape the landscape of therapeutic administration. His collaborations with esteemed colleagues highlight his ability to foster cooperation and drive progress within the industry. It is evident that Hans-Michael Wolff's inventive spirit and dedication to improving patient care make him an invaluable figure in the realm of transdermal drug delivery.